Understanding the New 2026 ACC Lipid Guidelines

Introducing the New Lipid Guidelines

The 2026 American College of Cardiology (ACC) lipid guidelines represent an important evolution in how we assess and manage cardiovascular risk. These updates reflect more recent clinical evidence with aims to improve prevention of heart attack and stroke through earlier identification and more personalized treatment strategies.

Why Guidelines Change Over Time

Medical guidelines are updated regularly, typically every 4-6 years, with interim updates as major studies are published. As new research emerges, our understanding of cardiovascular risk improves, and recommendations ideally evolve to reflect what most effectively reduces disease and improves outcomes.

So, What’s New in 2026?

Several key updates stand out to us:

• A Calculator Update: The new PREVENT risk calculator is designed to better estimate cardiovascular risk across broader populations. Though still evolving in clinical utility, the calculator estimates both 10-year and 30-year individual risk.
• ApoB and Lp(a) Emphasis: There is stronger recognition of Apolipoprotein B (ApoB) as a more accurate measure of atherogenic cholesterol particle burden, and Lipoprotein(a) as a genetically driven, independent risk factor. Both have been longtime standards of the BaleDoneen Method, so we are thrilled to see this practice moving into the mainstream.
• Earlier Testing and Treatment: The guidelines emphasize earlier screening and intervention, particularly in patients with cardiometabolic risk factors such as kidney disease, fatty liver disease and metabolic syndrome.
• Subclinical Atherosclerosis: The new guidelines recommend increased focus on identifying disease BEFORE symptoms arise, including use of imaging to detect early plaque buildup (CIMT, CACS mammography, brain imaging, AAA screening, etc.).

What We’re Excited About

We are particularly encouraged by any micro-shift toward prevention-focused care. The emphasis on ApoB and Lp(a) helps refine risk assessment beyond traditional cholesterol measures and is a huge win in our book. Recognition of subclinical disease (like plaque on a CIMT scan) allows for earlier, more proactive intervention before patients ever experience symptoms of cardiovascular disease.

The guidelines also highlight emerging evidence from trials like VESALIUS-CV, which supports treating high-risk patients far earlier, even in the absence of established cardiovascular disease.

Another positive aspect of the 2026 guidelines is a move toward expansion of the clinician’s “toolbelt” for proactively addressing lipid driven risk, including:

• Lifestyle interventions (always the most important)
• Statins
• Ezetimibe
• Bempedoic acid
• PCSK9 inhibitors
• GLP-1 receptor agonists

This expanded range of guidelines-supported options will hopefully drive insurance coverage for more individualized and comprehensive treatment plans.

What We’re LESS excited about

Despite improvements, some challenges remain. The PREVENT calculator can still be confusing, often generating multiple risk estimates, which can complicate decision-making. It may also underestimate risk in younger patients, especially those with significant cardiometabolic risk factors.

Notably, ApoB targets are not clearly defined, and Lp(a) is not yet included in the calculator, despite strong evidence of its impact on cardiovascular risk.

There may also be an over-reliance on the Coronary Artery Calcium Score (CACS), with less emphasis on modalities able to identify soft plaque (such as CT coronary angiography and CIMT scans), particularly relevant in younger patients. CAC scoring, while helpful, may provide false reassurance with a score of zero in younger individuals.

Final Thoughts

While guidelines provide a critical framework for evidence-based care, and often guide insurance coverage, medical decisions are never “one-size-fits-all.” These recommendations are not meant to replace clinical judgment. Instead, they provide a framework for informed, individualized discussions between provider and patient to determine the best approach for each unique situation. These guidelines represent an overall step in the right direction toward prevention, and will incrementally help BaleDoneen providers in our efforts to proactively provide personalized cardiovascular care.